Top 5 Stocks in George Soros’ Stock Portfolio

4. Novo Nordisk A/S (NYSE:NVO)

Novo Nordisk A/S (NYSE:NVO) is a Danish company that is engaged in developing, producing, and marketing pharmaceutical products.

On February 5, Novo Nordisk A/S (NYSE:NVO)’s parent company, Novo Holdings, announced that it would acquire Catalent, Inc. (NYSE:CTLT) in a deal worth $16.5 billion. After the acquisition is completed by year-end, the parent company will sell Catalent, Inc. (NYSE:CTLT)’s three ill-finish sites and other assets to the company.

On February 19, BofA raised the price target on Novo Nordisk A/S (NYSE:NVO)’s stock to DKK 975 from DKK 875 and kept a Buy rating on the shares.

Polen Capital commented on Novo Nordisk A/S (NYSE:NVO) in its fourth-quarter 2023 investor letter. Here is what it said:

“As we discussed in last quarter’s commentary, Novo Nordisk A/S (NYSE:NVO) is a newer addition to the strategy. Over the fourth quarter, we continued to build the position to an average weight. As a reminder, Novo Nordisk is a global pharmaceutical company based in Denmark and has long been the leader in developing insulin for diabetes patients. In recent years, the company’s innovation into GLP-1 drugs has been shown not only to help diabetics control blood sugar levels but also to have significant efficacy in weight loss. Obesity has become a global epidemic, creating materially negative knock-on effects for humans that range from an increase in cardiovascular events and, thus, higher mortality to a lower general quality of life. We believe that, over time, payors will recognize the value of these obesity treatments to both patients and the overall healthcare system.”